Turinabol is preferred by athletes because it offers a lot of benefits to experience slow, quality gains with fewer side effects than methandrostenolone. It has a positive impact on both nitrogen retention and protein synthesis . Turinabol helps to build red cells and increase the blood oxygenation and in turn, muscle endurance. The user experiences muscle gain that is both sustainable and significant. It is very effective in the cutting phase of a true off season cycle. It offers protection to the user against lean tissue loss and also increases muscle hardness. TuriGen 10 provides better stability and control regarding hormonal issues. Also it helps athletes to recover in the process of injuries. It provides decreased strain on ligaments and joints of the user.
Turinover Vermodje is a derivative of methandienone, but it altered chemical structure leads to large differences in the characteristics and effects. Both steroids are 17-alpha alkylated by the addition of carbon atom of 17-position in order to be able to "survive" the first passage through the liver. This, of course, increases the toxicity to the liver (hepatoxicity). But it has much lower androgenic activity than its sibling. According to the tables in "Androgens and Anabolic Agents: Chemistry and Pharmacology" Julius A. Vida, Turinabol has androgenic rating of 0 vs 53 for its anabolic properties. This provides more hardness, density and definition so sought after by competing bodybuilders.
Chlorodehydromethyltestosterone (CDMT) (brand title Oral Turinabol) is an androgenic-anabolic steroid. It's the 4-chloro-substituted by-product of metandienone (dehydromethyltestosterone) (Dianabol). CDMT was the primary unique product of Jenapharm, an East German pharmaceutical firm. The patent registration passed off in 1961. The thought of mixing the constructions of 4-chlorotestosterone (clostebol) and metandienone originated from the chemist Albert Stachowiak. On the time this represented a novel dissociation of anabolic and androgenic results after oral administration. The product had been launched for clinical use in 1965.